Biotech dealmaking is back in full swing, and for once, Wall Street’s punchline isn’t that the scientists made all the money and the shareholders got the placebo.
Biotech’s $100 Billion Revival
Biopharma M&A has roared back in 2026, with announced biotech and…
SpaceX’s march toward a record-smashing IPO is quickly turning into Wall Street’s favorite Rorschach test: one camp sees the dawn of a “trillion‑plus” space internet empire, the other sees a very expensive science project with a sky‑high multiple and a low Earth…
SpaceX’s long-awaited leap to the public markets is finally underway, and Wall Street is treating it less like a traditional IPO and more like the financial equivalent of a rocket launch countdown. With a Nasdaq listing planned under the ticker “SPCX,” Elon…
U.S. markets woke up to a strangely reassuring mix of higher builder cheer, pricier crude, a firmer dollar, and a rocket company doing what rockets do best—splitting the atmosphere, and now, its stock.
Housing: Confidence Rises, Affordability Still Bites
Homebuilder sentiment has…
Elon Musk’s SpaceX is finally inching toward the public markets, and in the process is threatening to turn the sleepy IPO calendar into something that looks more like a Falcon Heavy launch manifest.
A trillion here, a trillion there
Bankers who spent…
